| Authors/Year | Treatment | Result/Observations |
| Dasari, V.R. et al., 2014 Tukmachev, D. et al., 2015 Nejati-Koshki K. et al., 2017 | Stem Cells | Reduced defense cell action; Decreases apoptosis; Increase in growth factors; Secretion of trophic factors; Astrocyte proliferation and activation. |
| Zhang, L. and Webster, T.J. 2009 Pourhassan-Moghaddam, M. et al., 2014 Nejati-Koshki K. et al., 2017 | Nanotechnology | Neuroprotection; Increased drug bioavailability; Axonal regeneration; Imitation of the microenvironment. |
| Tsai, E.C. et al., 2006 Pangestuti, R. & Kim, S.-K., 2010 Rossi, F. et al., 2013 Macaya, D.J. et al., 2013 Wu, W. et al., 2014 Caron, I. et al., 2016 Nejati-Koshki K. et al., 2017 | Nanoparticles | Increased cell rescue; Combinations of treatments; Localized delivery of medicines; Beneficial for local stem cells; Provide a place for growth. |
| Lowry, N. et al., 2012 Ren, H. et al., 2014 Nejati-Koshki K., et al., 2017 | Polymeric Nanoparticles | Regulated drug release; Proper structuring of nervous tissue. |
| White-Schenk, D. et al., 2013 Nejati-Koshki K. et al., 2017 | Hydralazine + Nanoparticles | Secondary lesion of acrolein decreased; Reduced side effects. |
| Chavatal, S.A. et al., 2008 Kim, Y.-T. et al., 2009 Nejati-Koshki K., et al., (2017) | Methylprednisolone + Nanoparticles | Reduced side effects; Increased reported benefits. |
| Scott, J.B. et al., 2011 Li, X. et al., 2013 Thomas, A.M. et al., 2013 Pilehvar-Soltanahmadi, Y. et al., 2016 Nejati-Koshki K. et al., 2017 | Spinal Axonal Support | Axonal regeneration; Control in the delivery of drugs or molecules; Association with growth factors; Incorporation of specific cells of the nervous tissue. |
| Qiu et al., 2000 Goldberg and Barres, 2000 Fawcett, 2006 | IN-1 Antibody | Neutralizes NogoA; Increased neuroplasticity and regeneration. |